EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis.

Slides:

Advertisements

Similar presentations

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + Ribavirin in HCV GT 1,4 SOLAR-1 (Post Transplant) Phase 2 Treatment Naïve and Treatment.

Advertisements

Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV-HIV Coinfection: HCV GT 1,2,3,4 PHOTON-2 Trial Phase 3 Molina JM, et al. IAC. 2014;

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Weight-based Ribavirin in HCV GT 2,3 Phase 4 Treatment Naïve, Chronic HCV Zeuzem S, et.

Hepatitis web study Hepatitis web study Sofosbuvir, Ribavirin, GS-0938 in GT 1-4 QUANTUM Phase 2b Treatment Naïve Lalezari JP, et al. EASL. 2013; Abstract.

Hepatitis web study Hepatitis web study Ledipasvir + Sofosbuvir +/- Ribavirin in GT 1-3 ELECTRON 2 Phase 2 Treatment Naïve and Treatment Experienced Source:

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon + Ribavirin in Genotypes 1,4,5,6 ATOMIC Phase 2 Treatment Naïve Kowdley K, et al. Lancet.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV versus Interferon alfa-2b RIBAVIC STUDY Phase 3 Treatment Naïve, Chronic HCV and HIV.

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + RBV vs. Peginterferon alfa-2a + RBV IDEAL STUDY Phase 3, Treatment Naïve Treatment Naïve,

Hepatitis web study Hepatitis web study Hepatitis web study Hepatitis web study 3D (Ombitasvir-Paritaprevir-Ritonavir + Dasabuvir) + RBV in GT1 TURQUOISE-I.

Hepatitis web study Hepatitis web study Telaprevir in Treatment Naïve GT-1 ILLUMINATE (Study 111) Phase 3 Treatment Naïve Sherman KE, et. al. N Engl J.

Phase 3 Treatment Naïve and Treatment Experienced Renal Disease

Hepatitis web study Hepatitis web study Peginterferon alfa-2b + Ribavirin for 12 or 24 Weeks in GT 2,3 Phase 3 Treatment Naïve, Chronic HCV Mangia A, et.

Hepatitis web study Hepatitis web study Sofosbuvir in HCV-HIV Coinfection & HCV GT 1,2,3 PHOTON-1 Trial Phase 3 Sulkowski MS, et al. JAMA. 2014;312:

Hepatitis C Genotype 3 Paris 2012 Graham R Foster Professor of Hepatology Queen Marys School of Medicine Barts and The London.

Hepatitis web study Hepatitis web study Simeprevir in HIV Coinfection, GT-1 C212 Trial Phase 3 Treatment Naïve and Treatment Experienced Dieterich D, et.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV GT 4 Egyptian Ancestry Trial Phase 2 Ruane PJ, et al. J Hepatol. 2015;62:

PEGINTERFERON ALPHA-2A PLUS RIBAVIRIN VERSUS PEGINTERFERON ALPHA-2B PLUS RIBAVIRIN IN NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: RESULTS.

Hepatitis web study Hepatitis web study Telaprevir BID versus q8 in Treatment Naïve GT-1 OPTIMIZE (Study C211) Phase 3 Treatment Naïve Buti M, et al. Gastroenterology.

ELECTRON  Design SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ELECTRON Study: SOF-based therapy for genotypes 1, 2 and 3 W8W4W12 ≥ 19 years Chronic.

OBV/PTV/r Open label years Chronic HCV infection Genotype 1b Treatment-naïve or failure to PEG-IFN + RBV HCV RNA > 10,000 IU/ml Without or with cirrhosis*

Hepatitis web study Hepatitis web study Simeprevir with Peginterferon and Ribavirin in GT-4 RESTORE Phase 3 Treatment Naïve and Treatment Experienced Moreno.

How to optimize treatment of G1 patients? Prof. G. K. K. Lau 2012.

Placebo + PR W48 Placebo + PR Yes Hezode C. Gut 2015;64: COMMAND-1 COMMAND-1 Study: daclatasvir + PEG-IFN + RBV for genotype 1 or 4 DCV60 + PEG-IFN.

Hepatitis web study Hepatitis web study Sofosbuvir + Ribavirin in HCV Genotype 1 NIAID/NIH Trial Phase 2, Treatment Naïve Treatment Naïve (unfavorable.

SOLAR-2 LDV/SOF + RBV Randomisation of the 7 groups 1 : 1 Open-label SOLAR-2 Study: LDV/SOF + RBV in decompensated and post-liver transplant with genotype.

SOLAR-1 LDV/SOF + RBV Randomisation* of the 7 groups 1 : 1 Open-label SOLAR-1 Study: LDV/SOF + RBV in advanced liver disease  Design W12W24 ≥ 18 years.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

Hepatitis web study Hepatitis web study Simeprevir + Sofosbuvir in GT1 with Cirrhosis OPTIMIST-2 Trial Phase 3 Treatment Naïve and Treatment Experienced.

Sulkowski M. Lancet 2015;385: C-WORTHY  Design Randomisation* Open-label > 18 years HCV genotype 1, treatment naïve HCV RNA ≥ 10,000 IU/ml No cirrhosis.

Hepatitis web study Hepatitis web study Boceprevir with PEG + RBV in Genotype 1 SPRINT-1 Phase 2 Treatment Naïve Kwo PY, et al. Lancet. 2010;376:

LDV/SOF Failure Open-label W24 Chronic HCV infection Genotype 1 Failure to achieve SVR on LDV/SOF-containing regimen Compensated cirrhosis (liver biopsy.

Poordad F. NEJM 2014;368: D Phase IIa  Design  Treatment regimens – Paritaprevir/rironavir (PTV/r) : PTV 250 or 150 mg qd/ritonavir 100 mg qd (2.

Hepatitis web study Hepatitis web study Sofosbuvir + Peginterferon+ Ribavirin in HCV-HIV GT 1-4 Phase 2 Rodriguez-Torres M, et al. J Acquir Immune Defic.

PHOTON-1  Design  Objective –SVR 12 with 2-sided 95% CI, descriptive analysis –Multivariate analyses of predictors of SVR 12 SOF + RBV, N= 114 SOF +

به نام خداوند بخشنده مهربان. Treatment of HIV/HCV & HIV/HBV coinfection Dr. Davoudi Infectious diseases specialist Antimicrobial research center Mazandaran.

Phase 3 Treatment Experienced

Daclatasvir + Sofosbuvir +/- Ribavirin in Genotype 1-3 Trial

Design No randomisation Open-label W12 W years HCV genotype 1

Phase 3 Treatment-Naïve and Treatment-Experienced

Volume 63, Issue 1, Pages (July 2015)

Pipeline & HCV UK-CAB 31 January 2009.

Phase 3b Treatment-Naive

Phase 2b Treatment-Naïve

Phase 2 Treatment Naïve HIV Coinfection

HCV Care in Unique Patient Populations

بِسْمِ اللّهِ الرَّحْمَنِ الرَّحِيمِ )وَإِذَا مَرِضْتُ فَهُوَ يشْفِينِ( )سورة الشعراء – الاية 80) صدق الله العظيم.

HIV Management: An Update on the Latest EACS Guidelines

Figure 1 Patients cured of HCV infection

Simeprevir in HIV Coinfection, GT-1 C212 Trial

Out With the Old and In With the New, Again?

Phase 2 Treatment Naïve Elbasvir + Grazoprevir +/- Ribavirin in Treatment-Naïve HCV GT 2, 4, 5, or 6 C-SCAPE Brown A, et al. EASL 2015; Abstract P0771.

Ombitasvir + Paritaprevir + Ritonavir +/- Ribavirin in HCV GT4 PEARL-I

HCV Protease Inhibitors in Clinical Practice

New Agents, New Regimens, New Strategies

Care of the Treatment-naive Patient With HCV/HIV Coinfection

Daclatasvir + Peg/RBV in Treatment-Naïve Genotype 4 COMMAND-4 Study

Ledipasvir-Sofosbuvir +/- Ribavirin for 8 or 12 weeks in HCV GT1 ION-3

Phase 2b Treatment Naïve and Treatment Experienced

Elbasvir/Grazoprevir plus Sofosbuvir ± Ribavirin in Treatment-naive and Treatment-experienced Patients with Hepatitis C Virus Genotype 3 Infection and.

Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection

Advances in the Treatment of HCV Genotype 3 and HIV/HCV Coinfection

Volume 138, Issue 1, Pages (January 2010)

HCV Protease Inhibitors in Clinical Practice

What do data in monoinfection mean in relation to co-infection?

Genetic Factors and Hepatitis C Virus Infection

Phase 2 Treatment Experienced (with Sofosbuvir and Ribavirin)

Volume 63, Issue 1, Pages (July 2015)

Phase 3 Treatment-Naïve and Treatment-Experienced

Survival benefits of DAA in patients with decompensated cirrhosis

Presentation transcript:

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis C without cirrhosis, including treatment-naïve patients and patients who failed on a treatment based on PegIFN-a and ribavirin (RBV)

EASL Recommendations on Treatment of Hepatitis C 2015 Treatment recommendations for HCV-monoinfected or HCV/HIV coinfected patients with chronic hepatitis C with compensated (Child-Pugh A) cirrhosis, including treatment-naïve patients and patients who failed on a treatment based on PegIFN-a and ribavirin (RBV)